ArticleScientific reports2017
The N-terminal domain of Schmallenberg virus envelope protein Gc is highly immunogenic and can provide protection from infection.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 42 citations in OpenAlex.
- Review
- Protein-based tools for the detection and characterisation of Oropouche virus infection.EMBO molecular medicine · 2025Article
- Research Progress on the Gc Proteins of Akabane Virus.Veterinary sciences · 2025Review
- Addressing the emerging threat of Oropouche virus: implications and public health responses for healthcare systems.Tropical diseases, travel medicine and vaccines · 2025Review
- Schmallenberg virus epidemiology and regional control strategies: diagnostics, vaccines, and vector management.Frontiers in cellular and infection microbiology · 2025Review
- Insights into the expansion of Oropouche virus in Brazil: epidemiological and environmental aspects.Experimental biology and medicine (Maywood, N.J.) · 2025Review
- Oropouche virus: A neglected global arboviral threat.Virus research · 2024Review
- Generation of Stable Cell Lines Expressing Akabane Virus N Protein and Insight into Its Function in Viral Replication.Pathogens (Basel, Switzerland) · 2023Article
- Vaccine development against Schmallenberg virus: from classical inactivated to modified-live to scaffold particle vaccines.One health outlook · 2022Review
- Two Akabane virus glycoprotein Gc domains induce neutralizing antibodies in mice.The Journal of veterinary medical science · 2022Article
- Article
- Recovery of Two Replication-Competent Canine Distemper Viruses That Separately Express Dabie Bandavirus Gn and Gc.Frontiers in veterinary science · 2022Article
- Article
- Development of a Modular Vaccine Platform for Multimeric Antigen Display Using an Orthobunyavirus Model.Vaccines · 2021Article
- Differentiation of Antibodies against Selected Simbu Serogroup Viruses by a Glycoprotein Gc-Based Triplex ELISA.Veterinary sciences · 2021Article
- High genetic variability of Schmallenberg virus M-segment leads to efficient immune escape from neutralizing antibodies.PLoS pathogens · 2021Article
- A novel Schmallenberg virus subunit vaccine candidate protects IFNARScientific reports · 2020Article
- Schmallenberg Virus: To Vaccinate, or Not to Vaccinate?Vaccines · 2020Review
- Article
- Reverse Genetics System for Shuni Virus, an Emerging Orthobunyavirus with Zoonotic Potential.Viruses · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schmallenberg virus (SBV) is transmitted by insect vectors, and therefore vaccination is one of the most important tools of disease control. In our study, novel subunit vaccines on the basis of an amino-terminal domain of SBV Gc of 234 amino acids ("Gc Amino") first were tested and selected using a lethal small animal challenge model and then the best performing formulations also were tested in cattle. We could show that neither E. coli expressed nor the reduced form of "Gc Amino" protected from SBV infection. In contrast, both, immunization with "Gc Amino"-encoding DNA plasmids and "Gc-amino" expressed in a mammalian system, conferred protection in up to 66% of the animals. Interestingly, the best performance was achieved with a multivalent antigen containing the covalently linked Gc domains of both, SBV and the related Akabane virus. All vaccinated cattle and mice were fully protected against SBV challenge infection. Furthermore, in the absence of antibodies against the viral N-protein, differentiation between vaccinated and field-infected animals allows an SBV marker vaccination concept. Moreover, the presented vaccine design also could be tested for other members of the Simbu serogroup and might allow the inclusion of additional immunogenic domains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.